{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T05:21:51Z","timestamp":1792214511600,"version":"4.4.0"},"reference-count":21,"publisher":"American Medical Association (AMA)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"<jats:sec id=\"ab-zoi260680-4\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Troponin monitoring is recommended for the early detection of immune checkpoint inhibitor (ICI)\u2013associated myocarditis, but its utility as a universal screening tool for all cardiovascular (CV) toxic effects in patients with cancer treated with ICIs remains uncertain.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-zoi260680-5\">\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate whether systematic troponin screening is associated with reduced major adverse CV events (MACEs) and mortality in patients receiving ICI therapy for cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-zoi260680-6\">\n                    <jats:title>Design, Setting, and Participants<\/jats:title>\n                    <jats:p>This retrospective, multicenter cohort study assessed adults treated with ICIs between January 1, 2017, and December 31, 2022, at 2 tertiary oncology centers. Patients undergoing systematic troponin screening (\u22652 measurements during the first trimester of ICI therapy not prompted by symptoms) were compared with those undergoing clinical assessment without screening. Cross-sectional follow-up was undertaken between June 1, 2023, and June 30, 2024.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-zoi260680-7\">\n                    <jats:title>Exposure<\/jats:title>\n                    <jats:p>ICI therapy for solid cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-zoi260680-8\">\n                    <jats:title>Main Outcomes and Measures<\/jats:title>\n                    <jats:p>The primary outcomes included adjudicated MACEs (ICI-associated myocarditis, acute coronary syndrome, heart failure requiring hospitalization, sudden cardiac death, and CV death). Multivariate Cox proportional hazards regression, Fine-Gray competing risk models, and propensity score matching were applied, with death from cancer considered a competing risk.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-zoi260680-9\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of 859 patients (mean [SD] age, 70.1\u2009[10.8] years; 517 [60.2%] male; 585 [68.1%] with lung cancer), 40 (4.7%) developed MACEs, including 6 (0.7%) with ICI-associated myocarditis; 484 (56.3%) died at a median follow-up of 3.3 (IQR, 1.3-7.2) months, mainly from cancer (436 [90.1%]). Routine troponin screening was associated with lower mortality combined with MACEs in multivariable models (hazard ratio, 0.56 [95% CI, 0.45-0.70]) (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009&amp;amp;lt;\u2009.001) but was not associated with MACEs after competitive risk analysis (hazard ratio, 0.56 [95% CI, 0.20-1.55]) (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009=\u2009.27) or in a propensity score\u2013matched cohort of 354 patients (hazard ratio, 0.49 [95% CI, 0.20-1.24]) (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009=\u2009.13).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-zoi260680-10\">\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>In this cohort study, systematic troponin screening was not associated with MACEs in an older population with metastatic solid cancer after competitive risk analysis or propensity score matching. These findings suggest that the benefits of universal troponin monitoring are questionable among unselected patients with cancer who are receiving ICIs; further investigation is needed to determine whether risk-adapted screening improves outcomes while avoiding unnecessary interruptions of treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2026.24168","type":"journal-article","created":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T15:00:19Z","timestamp":1784646019000},"page":"e2624168","source":"Crossref","is-referenced-by-count":1,"title":["Troponin Screening and Major Cardiovascular Adverse Events During Immune Checkpoint Inhibitor Therapy"],"prefix":"10.1001","volume":"9","author":[{"given":"Imen","family":"Hamdi","sequence":"first","affiliation":[{"name":"Department of Cardiology, Institut Montsouris, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"El B\u00e8ze","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Institut Montsouris, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soledad","family":"Henriquez","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Institut Montsouris, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Liesse","family":"Joulia","sequence":"additional","affiliation":[{"name":"Department of Oncology, Institut Montsouris, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rapha\u00ebl","family":"Colle","sequence":"additional","affiliation":[{"name":"Department of Oncology, Institut Montsouris, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine","family":"Loirat","sequence":"additional","affiliation":[{"name":"Department of Oncology, Institut Curie, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Girard","sequence":"additional","affiliation":[{"name":"Department of Oncology, Institut Curie, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agn\u00e8s","family":"Lillo Le Louet","sequence":"additional","affiliation":[{"name":"Department of Pharmacovigilance, H\u00f4pital Europ\u00e9en Georges Pompidou- University Paris Cit\u00e9, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Caussin","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Institut Montsouris, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Mirabel","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Institut Montsouris, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2026,7,21]]},"reference":[{"issue":"12","key":"zoi260680r1","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1016\/S1470-2045(18)30608-9","article-title":"Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study.","volume":"19","author":"Salem","year":"2018","journal-title":"Lancet Oncol"},{"issue":"10","key":"zoi260680r2","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1002\/ejhf.3340","article-title":"Cardiovascular toxicities of immune therapies for cancer\u2014a scientific statement of the Heart Failure Association (HFA) of the ESC and the ESC Council of Cardio-Oncology.","volume":"26","author":"Tocchetti","year":"2024","journal-title":"Eur J Heart Fail"},{"issue":"7937","key":"zoi260680r3","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1038\/s41586-022-05432-3","article-title":"T cells specific for a-myosin drive immunotherapy-related myocarditis.","volume":"611","author":"Axelrod","year":"2022","journal-title":"Nature"},{"issue":"41","key":"zoi260680r5","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS).","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur Heart J"},{"issue":"8","key":"zoi260680r6","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1007\/s00392-024-02462-x","article-title":"Adverse myocardial and vascular side effects of immune checkpoint inhibitors: a prospective multimodal cardiovascular assessment.","volume":"113","author":"Mirabel","year":"2024","journal-title":"Clin Res Cardiol"},{"key":"zoi260680r7","doi-asserted-by":"publisher","first-page":"2299","DOI":"10.1161\/CIRCULATIONAHA.120.049981","article-title":"Association between immune checkpoint inhibitors with cardiovascular events and atherosclerotic plaque.","volume":"142","author":"Drobni","year":"2020","journal-title":"Circulation"},{"key":"zoi260680r8","doi-asserted-by":"publisher","DOI":"10.1016\/j.acvd.2025.06.073","article-title":"Cardiovascular safety of a standardized outpatient triage and diagnostic approach for suspected cardiovascular immune-related adverse events of immune checkpoint inhibitors.","author":"Cribari","year":"2025","journal-title":"Arch Cardiovasc Dis"},{"key":"zoi260680r9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.115186","article-title":"Optimized monitoring for immune checkpoint inhibitor induced myocarditis using high-sensitivity troponin-T.","volume":"216","author":"Tomsitz","year":"2025","journal-title":"Eur J Cancer"},{"issue":"3","key":"zoi260680r10","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.acvd.2024.12.012","article-title":"Diagnosis of cancer therapy-related cardiovascular toxicities: a multimodality integrative approach and future developments.","volume":"118","author":"Travers","year":"2025","journal-title":"Arch Cardiovasc Dis"},{"issue":"1","key":"zoi260680r11","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.jaccao.2021.01.004","article-title":"Myocarditis surveillance with high-sensitivity troponin I during cancer treatment with immune checkpoint inhibitors.","volume":"3","author":"Waliany","year":"2021","journal-title":"JACC CardioOncol"},{"issue":"9","key":"zoi260680r12","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1093\/eurheartj\/ehaf682","article-title":"Incidence and risk factors of immune checkpoint inhibitor myocardial and muscle toxicity: a French nationwide study.","volume":"47","author":"Salem","year":"2026","journal-title":"Eur Heart J"},{"key":"zoi260680r13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccao.2025.06.009","article-title":"Cardiac troponin screening and clinical outcomes in patients receiving immunotherapy.","author":"Cheng","year":"2025","journal-title":"JACC CardioOncology"},{"issue":"20","key":"zoi260680r15","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.","volume":"310","author":"World Medical Association","year":"2013","journal-title":"JAMA"},{"issue":"2","key":"zoi260680r16","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.013757","article-title":"Immune checkpoint inhibitor myocarditis: pathophysiological characteristics, diagnosis, and treatment.","volume":"9","author":"Palaskas","year":"2020","journal-title":"J Am Heart Assoc"},{"issue":"2","key":"zoi260680r17","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1161\/CIRCULATIONAHA.118.034497","article-title":"Myocarditis in the setting of cancer therapeutics: proposed case definitions for emerging clinical syndromes in cardio-oncology.","volume":"140","author":"Bonaca","year":"2019","journal-title":"Circulation"},{"issue":"38","key":"zoi260680r18","doi-asserted-by":"publisher","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","article-title":"2023 ESC Guidelines for the management of acute coronary syndromes.","volume":"44","author":"Byrne","year":"2023","journal-title":"Eur Heart J"},{"issue":"36","key":"zoi260680r19","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure.","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"zoi260680r20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.114191","article-title":"Prospective cardiovascular events in patients with advanced thoracic cancer treated with immune checkpoint inhibitor.","volume":"207","author":"Toublanc","year":"2024","journal-title":"Eur J Cancer"},{"issue":"9","key":"zoi260680r21","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1093\/eurheartj\/ehaf315","article-title":"Immune checkpoint inhibitor-associated myocarditis: a novel risk score.","volume":"47","author":"Power","year":"2026","journal-title":"Eur Heart J"},{"key":"zoi260680r4","doi-asserted-by":"crossref","unstructured":"Power? JR, Dolladille? C, Ozbay? B, . Predictors and risk score for immune checkpoint-inhibitor-associated myocarditis severity.? MedRxiv. Preprint published online June 3, 2024. doi:10.1101\/2024.06.02.24308336?","DOI":"10.1101\/2024.06.02.24308336"},{"key":"zoi260680r14","unstructured":"Troponin to detect major cardiovascular adverse events on immune checkpoint inhibitors (TILT). ClinicalTrials.gov identifier: NCT06007274. Updated April 8, 2026. Accessed January 1, 2026. https:\/\/clinicaltrials.gov\/study\/NCT06007274"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2851864\/hamdi_2026_oi_260680_1784056160.69449.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T15:00:20Z","timestamp":1784646020000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2851864"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,21]]},"references-count":21,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2026.24168","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,21]]}}}